Recent experimental studies showed that activated macrophages/microglia (AMM) express
excitatory amino acid transporters (EAATs), suggesting that, in addition to their neurotoxic properties, they also have a neuroprotective role by clearing extracellular
glutamate and producing
antioxidant glutathione. To test this hypothesis in human, the brain of 12 HIV-positive patients and 3 controls were immunostained for EAAT-1. EAAT-1 was expressed by AMM in all HIV-infected cases but not in HIV-negative controls. Expression varied according to the disease stage. In 5 cases with active HIV-
encephalitis (HIVE), AMM strongly expressed EAAT-1 in the white matter and basal ganglia, analogous to
HLA-DR and CD68 expression. There was weaker expression in the cortex and perineuronal microglial cells were not involved. In a case with "burnt out" HIVE following
highly active antiretroviral therapy (
HAART), EAAT-1 expression was mild, identical to that of
HLA-DR and CD68 in the white matter and cortex and involved perineuronal microglial cells. In 3
AIDS patients without HIVE and in 3 pre-
AIDS cases, EAAT-1 expression in the white matter was weaker than
HLA-DR and CD68 expression; there was stronger correlation in the gray matter where perineuronal microglial cells were stained predominantly. Our findings in humans tend to confirm that AMM, particularly perineuronal microglial cells, play a neuroprotective role in the early stages of
HIV infection and, possibly, following treatment. This is in keeping with the early microglial activation seen in pre-
AIDS cases, and the late occurrence of neuronal loss. It may also explain the reversible
cognitive disorders following treatment in some cases.